SSTR2 and neoplasm: The ability of [177Lu]Lu-OPS201 to recognise more binding sites compared with [177Lu]Lu-DOTA-TATE supports the use of radiolabelled SST2 antagonists not only in all NENs, including high grades, but also in tumours with lower SST2 density such as breast and small cell lung cancers [5], which is not the case for [177Lu]Lu-DOTA-TATE.